01 F. Hoffmann – La Roche

Roche Logo

Grenzacherstraße 124
CH-4070 Basel


Participant's Lead

Will Spooren

Dr. Will Spooren
Group Leader Behavioral Pharmacology
Phone: +41 61 688 6350
Fax: +41 61 687 9862

Research Gate

Project Staff

Omar Kwhaja

Xavier Liogier d'Arhuy, PhD
Roche Pharmaceutical Research and Early Development
Neuroscience, Ophthalmology and Rare Diseases
EFPIA Leads of WP04
Phone: +41 61 688 8095
Fax: +41 61 687 9848

Omar Kwhaja

Lauren Boak
Translational Medicine Principal Scientist, NORD;
Phone: +41 61 688 29002
Fax: +41 79 359681 13

Partner Presentation

Headquartered in Basel, Switzerland, Roche is one of the world?s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market. Roche employs roughly 65,000 people in 150 countries. The CNS group in Roche has expertise in the areas of autism spectrum disorder, alzheimer?s disease, schizophrenia, depression, and imaging which spans from discovery where Roche scientists have made major advancements in identifying pathways involved in ASD, schizophrenia and depression to the clinic where innovative new first-in-class medications are being developed for these major psychiatric disorders. The CNS group at Roche is committed to contribute to the success of the IMI project by providing its expertise in several areas of interest including but not limited to: pharmaco MRI and preclinical studies where we will provide expertise in designing and performing experiments with animal models, PET ligand development where we will contribute to the development of novel radioligands through our expertise in several methods which include: synthesis of precursors, tritium radiolabeling, autoradiography, and in vivo binding. We will also contribute by providing genetic analysis including GWAS, CNV and transcriptional data and phenotypic characteristics from our clinical samples.